Drugs / Menatetrenone
Menatetrenone
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00165633 | Mar 2004 → Mar 2007 | hepatocellular carcinoma | Eisai Inc. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00062595 | Sep 2000 → Oct 2004 | osteoporosis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT00960973 | Sep 2009 → Dec 2010 | diabetes mellitus, prediabetes syndrome | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00548509 | Feb 2002 → Jan 2013 | osteoporosis | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00165607 | Apr 1996 → Jun 2005 | osteoporosis | Eisai Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05360342 | Mar 2020 → Jul 2021 | vitamin K deficiency hemorrhagic disease | RWTH Aachen University | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT01232647 Comparator | Apr 2015 → Mar 2020 | postmenopausal osteoporosis | Guy's and St Thomas' NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 3 | NCT00165698 Comparator | May 2005 → Jan 2007 | postmenopausal osteoporosis | Eisai Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-05-25 | Eisai Inc. | Regulatory SANNOVA RECEIVES APPROVAL FOR ADDITIONAL INDICATION, ADDITIONAL DOSAGE AND ADMINISTRATION OF KAYTWO® SYRUP 0.2% FOR PREVENTION OF VITAMIN K DEFICIENCY HEMORRHAGE IN NEONATES AND INFANTS eisai.com ↗
has received approval for an additional indication and additional dosage and administration of its vitamin K 2 syrup formulation, Kaytwo® Syrup 0.2% (menatetrenone), for the prevention of vitamin K deficiency hemorrhage in neonates and infants. |
All press releases naming this drug 2 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | menatetrenone | “To determine the effect and safety of menatetrenone on treatment of postmenopausal osteoporosis comparing with alfacalcidol.” NCT00165698 ↗ |
| Known as | menaquinone-4 | “The vitamin K supplement contains 3 subforms of vitamin K: vitamin K1 (1000µg), menaquinone-4 (1000µg) and menaquinone-7 (200µg).” NCT05360342 ↗ |
| Known as | MENATETRANONE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00165607 ↗ |
| Known as | MK4 | “Menatetrenone (MK4) 45 mg daily” NCT01232647 ↗1“menatetranone (MK4)” NCT00062595 ↗ |
| Known as | Vitamin K2 | “Menatetrenone (Vitamin K2)” NCT00548509 ↗ |
| Route | Oral | “Study drug was administered orally” NCT00165633 ↗ |